Drug allergy epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
{{CMG}} {{AE}} {{CP}} | |||
{{Drug allergy}} | {{Drug allergy}} | ||
Revision as of 21:46, 13 February 2013
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2]
|
Drug Allergy |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Drug allergy epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Drug allergy epidemiology and demographics |
|
Risk calculators and risk factors for Drug allergy epidemiology and demographics |
Overview
Adverse drug reactions may occur in up to 10% of the worldwide population, and also affect up to 20% of patients who are hospitalized. Of all the cases of fatalities caused by anaphylaxis, drugs may be responsible for 20% of the deaths. The incidence of toxic epidermal necrolysis is about 0.4-1.2 cases per million in a year.